Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation
Victoria DeMambro(MaineHealth), David R. Clemmons(University of North Carolina at Chapel Hill)
Cited by 44
Related Papers
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Guidelines for Acromegaly Management: An Update
|The Journal of Clinical Endocrinology & Metabolism|2009|763
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
|The Lancet|2001|643
Evaluation of Acromegaly by Radioimmunoassay of Somatomedin-C
|New England Journal of Medicine|1979|367
Reduction of Plasma Immunoreactive Somatomedin C during Fasting in Humans*
|The Journal of Clinical Endocrinology & Metabolism|1981|366